lifestyle.longislandreport.org

Author: Dewpoint Therapeutics

Dewpoint Therapeutics Reports Preclinical Data on Oral MYC Condensate Modulator at AACR 2026

April 21, 2026
Dewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate

February 13, 2026
Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer

February 10, 2026